Pfizer to Supply Up to 740M Additional Doses Of Prevenar 13 to World's Poorest Countries

Pfizer Inc. PFE welcomes today's announcement from the GAVI Alliance regarding the signing of a new supply agreement for Pfizer to provide additional doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company's 13-valent pneumococcal conjugate vaccine, for use in infants and young children to help protect against pneumococcal disease1 in the world's poorest countries under the terms of the Advance Market Commitment (AMC). Pneumococcal disease is one of the leading causes of vaccine-preventable deaths worldwide in children younger than 5 years of age.2 Prevenar 13 is a vaccine that helps protect against the 13 strains of pneumococcal disease that are included in the vaccine. In the United States, it is known as Prevnar 13 and is used for See full press release